Literature DB >> 33523799

Phage display reloaded: on the development of reliable monoclonal antibodies for potential Rh immune globulin production.

Gregory A Denomme1.   

Abstract

Mesh：

Substances：

Year:  2021        PMID： 33523799      PMCID： PMC7850917          DOI： 10.2450/2021.0354-20

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  10 in total

1.  Germline variable region gene segment derivation of human monoclonal anti-Rh(D) antibodies. Evidence for affinity maturation by somatic hypermutation and repertoire shift.

Authors:  J M Bye; C Carter; Y Cui; B D Gorick; S Songsivilai; G Winter; N C Hughes-Jones; J D Marks
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

Review 2.  A review of monoclonal antibody therapies in lymphoma.

Authors:  Esmeralda Chi-yuan Teo; Yveline Chew; Colin Phipps
Journal:  Crit Rev Oncol Hematol       Date:  2015-08-10       Impact factor: 6.312

3.  Consistent manufacturing and quality control of a highly complex recombinant polyclonal antibody product for human therapeutic use.

Authors:  Torben P Frandsen; Henrik Naested; Søren K Rasmussen; Peter Hauptig; Finn C Wiberg; Lone Kjaer Rasmussen; Anne Marie Valentin Jensen; Pia Persson; Margareta Wikén; Anders Engström; Yun Jiang; Susan J Thorpe; Cecilia Förberg; Anne B Tolstrup
Journal:  Biotechnol Bioeng       Date:  2011-04-25       Impact factor: 4.530

4.  Aggregates in blood filter chambers used from the plasma donations of anti-D donors: evaluation for monoclonal antibody discovery using phage display.

Authors:  Eunike C McGowan; Robert L Flower; Martina L Jones; David O Irving; Ross T Barnard; Catherine A Hyland; Stephen M Mahler; Xuan T Bui
Journal:  Blood Transfus       Date:  2020-10-09       Impact factor: 3.443

Review 5.  Review of monoclonal antibody therapies in asthma and allergic diseases - a new paradigm for precision medicine.

Authors:  Tak Lee; Parameswaran Nair; Christopher John Corrigan
Journal:  Asian Pac J Allergy Immunol       Date:  2020-06       Impact factor: 2.310

6.  Human monoclonal antibodies encoded by the V4-34 gene segment show cold agglutinin activity and variable multireactivity which correlates with the predicted charge of the heavy-chain variable region.

Authors:  S J Thorpe; C E Turner; F K Stevenson; M B Spellerberg; R Thorpe; J B Natvig; K M Thompson
Journal:  Immunology       Date:  1998-01       Impact factor: 7.397

7.  Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia.

Authors:  Tadeusz Robak; Jerzy Windyga; Jacek Trelinski; Mario von Depka Prondzinski; Aristoteles Giagounidis; Chantal Doyen; Ann Janssens; María Teresa Alvarez-Román; Isidro Jarque; Javier Loscertales; Gloria Pérez Rus; Andrzej Hellmann; Wieslaw Wiktor Jêdrzejczak; Kazimierz Kuliczkowski; Lana M Golubovic; Dusica Celeketic; Andrei Cucuianu; Emanuil Gheorghita; Mihaela Lazaroiu; Ofer Shpilberg; Dina Attias; Elena Karyagina; Kalinina Svetlana; Kateryna Vilchevska; Nichola Cooper; Kate Talks; Mukhyaprana Prabhu; Prasad Sripada; T P R Bharadwaj; Henrik Næsted; Niels J Ø Skartved; Torben P Frandsen; Mimi F Flensburg; Peter S Andersen; Jørgen Petersen
Journal:  Blood       Date:  2012-08-20       Impact factor: 22.113

8.  Antibody-mediated immune suppression is improved when blends of anti-RBC monoclonal antibodies are used in mice.

Authors:  Lidice Bernardo; Alaa Amash; Danielle Marjoram; Alan H Lazarus
Journal:  Blood       Date:  2016-06-21       Impact factor: 22.113

9.  Human Rh D monoclonal antibodies (BRAD-3 and BRAD-5) cause accelerated clearance of Rh D+ red blood cells and suppression of Rh D immunization in Rh D- volunteers.

Authors:  B M Kumpel; M J Goodrick; D H Pamphilon; I D Fraser; G D Poole; C Morse; G R Standen; G E Chapman; D P Thomas; D J Anstee
Journal:  Blood       Date:  1995-09-01       Impact factor: 22.113

Review 10.  Filamentous fusion phage cloning vectors for the study of epitopes and design of vaccines.

Authors:  S F Parmley; G P Smith
Journal:  Adv Exp Med Biol       Date:  1989       Impact factor: 2.622
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.